Skip to main content
Top
Published in: Clinical Rheumatology 3/2006

01-05-2006 | Original Article

Incidence and clinical correlation of anticentromere antibody in Thai patients

Authors: Krisaree Pakunpanya, Oravan Verasertniyom, Monchand Vanichapuntu, Prapaporn Pisitkun, Kitti Totemchokchyakarn, Kanokrat Nantiruj, Suchela Janwityanujit

Published in: Clinical Rheumatology | Issue 3/2006

Login to get access

Abstract

Anticentromere antibodies (ACA) are useful in assessing and classifying patients with mild variant of systemic sclerosis called calcinosis, Raynaud's phenomenon, esophageal dysmotility, sclerodactyly, telangiectasias (CREST) syndrome. From their prognostic significance, we are interested in the prevalence and disease correlation in Thai patients. A total of 3,233 serum samples of patients with any musculoskeletal symptoms were sent for antinuclear antibody determination at Ramathibodi Immunology Laboratory Service between the years 1998 and 2001. Forty sera (1.23%) were ACA positive. These sera were from 27 patients with autoimmune diseases and 13 with nonautoimmune diseases. Among autoimmune group, scleroderma was the most common diagnosis (33.3%) with limited sclerosis being the most frequent variant. The percentages of autoimmune disease were almost the same among the low-titer (1:40) and the high-titer (1:640) groups. The study suggests that the prevalence of ACA in Thai patients is low. The presence of ACA detected in patients with vague musculoskeletal symptoms does not suggest a diagnosis of CREST syndrome. Even high-titer ACA can be found in nonautoimmune diseases.
Literature
1.
go back to reference Tan EM, Rodnan GP, Garcia I, Moroi Y, Fritzler MJ, Peebles C (1980) Diversity of antinuclear antibodies in progressive systemic sclerosis: anticentromere antibody and its relationship to CREST syndrome. Arthritis Rheum 23:617–625PubMedCrossRef Tan EM, Rodnan GP, Garcia I, Moroi Y, Fritzler MJ, Peebles C (1980) Diversity of antinuclear antibodies in progressive systemic sclerosis: anticentromere antibody and its relationship to CREST syndrome. Arthritis Rheum 23:617–625PubMedCrossRef
2.
go back to reference Fritzler MJ, Kinsella TD (1980) The CREST syndrome: a distinct serologic entity with anticentromere antibodies. Am J Med 69:520–526CrossRefPubMed Fritzler MJ, Kinsella TD (1980) The CREST syndrome: a distinct serologic entity with anticentromere antibodies. Am J Med 69:520–526CrossRefPubMed
3.
go back to reference Tuffanelli DL, McKeon F, Kleinsmith DM, Burnham TK, Kirschner M (1983) Anticentromere and anticentriole antibodies in the scleroderma spectrum. Arch Dermatol 119:560–566CrossRefPubMed Tuffanelli DL, McKeon F, Kleinsmith DM, Burnham TK, Kirschner M (1983) Anticentromere and anticentriole antibodies in the scleroderma spectrum. Arch Dermatol 119:560–566CrossRefPubMed
4.
go back to reference Vazquez-Abad D, Grodzicky T, Senecal JL (1999) Anticentromere autoantibodies in patients without Raynaud's disease or systemic sclerosis. Clin Immunol 90:182–189CrossRefPubMed Vazquez-Abad D, Grodzicky T, Senecal JL (1999) Anticentromere autoantibodies in patients without Raynaud's disease or systemic sclerosis. Clin Immunol 90:182–189CrossRefPubMed
5.
go back to reference Chan HL, Lee YS, Hong HS, Kuo TT (1994) Anticentromere antibodies (ACA): clinical distribution and disease specificity. Clin Exp Dermatol 19:298–302PubMedCrossRef Chan HL, Lee YS, Hong HS, Kuo TT (1994) Anticentromere antibodies (ACA): clinical distribution and disease specificity. Clin Exp Dermatol 19:298–302PubMedCrossRef
6.
go back to reference Sato S, Fujimoto M, Ihn H, Takehara K (1994) Antibodies to centromere and centriole in scleroderma spectrum disorders. Dermatology 189:23–26PubMedCrossRef Sato S, Fujimoto M, Ihn H, Takehara K (1994) Antibodies to centromere and centriole in scleroderma spectrum disorders. Dermatology 189:23–26PubMedCrossRef
7.
go back to reference Maricq HR, Weinrich MC, Keil JE, Smith EA, Harper FE, Nussbaum AI et al (1989) Prevalence of scleroderma spectrum disorders in the general populations of South Carolina. Arthritis Rheum 32:998–1002PubMedCrossRef Maricq HR, Weinrich MC, Keil JE, Smith EA, Harper FE, Nussbaum AI et al (1989) Prevalence of scleroderma spectrum disorders in the general populations of South Carolina. Arthritis Rheum 32:998–1002PubMedCrossRef
8.
go back to reference Medsger TA (1994) Systemic sclerosis (scleroderma). In: Stein JH, Hutton JJ. Kohler Po et al (eds). Internal medicine, 4th edn. Mosby Year Book, St. Louise, MO, pp 2443–2449 Medsger TA (1994) Systemic sclerosis (scleroderma). In: Stein JH, Hutton JJ. Kohler Po et al (eds). Internal medicine, 4th edn. Mosby Year Book, St. Louise, MO, pp 2443–2449
9.
go back to reference Kallenberg CGM, Pastoor GW, Wouda AA et al (1982) Antinuclear antibodies in patients with Raynaud's phenomenon: clinical significance of anticentromere antibodies. Ann Rheum Dis 41:382–387PubMedCrossRef Kallenberg CGM, Pastoor GW, Wouda AA et al (1982) Antinuclear antibodies in patients with Raynaud's phenomenon: clinical significance of anticentromere antibodies. Ann Rheum Dis 41:382–387PubMedCrossRef
10.
go back to reference Chorzelski TP, Jablonska S, Beutner EH, Blaszczyk M, Jarzabek-Chorzelska M, Kencha D et al (1985) Anticentromere antibody: an immunological marker of a subset of systemic sclerosis. Br J Dermatol 113:381–9PubMedCrossRef Chorzelski TP, Jablonska S, Beutner EH, Blaszczyk M, Jarzabek-Chorzelska M, Kencha D et al (1985) Anticentromere antibody: an immunological marker of a subset of systemic sclerosis. Br J Dermatol 113:381–9PubMedCrossRef
11.
go back to reference Powell FC, Winkelmann RK, Venencie-Lemarchand F, Spurbeck JL, Schroeter AL (1984) The anticentromere antibody: disease specificity and clinical significance. Mayo Clin Proc 59:700–706 Powell FC, Winkelmann RK, Venencie-Lemarchand F, Spurbeck JL, Schroeter AL (1984) The anticentromere antibody: disease specificity and clinical significance. Mayo Clin Proc 59:700–706
12.
go back to reference Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee (1980) Preliminary criteria for the classification of systemic sclerosis (scleroderrma). Arthritis Rheum 23:581–590CrossRef Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee (1980) Preliminary criteria for the classification of systemic sclerosis (scleroderrma). Arthritis Rheum 23:581–590CrossRef
13.
go back to reference Arnett FC, Edworthy SM, Block DA, Mcshane DJ, Fries JF, Cooper NS et al (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315–324PubMedCrossRef Arnett FC, Edworthy SM, Block DA, Mcshane DJ, Fries JF, Cooper NS et al (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315–324PubMedCrossRef
14.
go back to reference Vlachoyiannopauplos PG, Drosos AA, Wiik A, Moutsopoulos HM (1993) Patients with anticentromere antibodies, clinical features, diagnoses and evolution. Br J Rheumatol 32:297–301PubMedCrossRef Vlachoyiannopauplos PG, Drosos AA, Wiik A, Moutsopoulos HM (1993) Patients with anticentromere antibodies, clinical features, diagnoses and evolution. Br J Rheumatol 32:297–301PubMedCrossRef
15.
go back to reference Caramaschi P, Biasi D, Manzo T, Carletto A, Poli F, Bambara LM (1995) Anticentromere antibody-clinical associations: a study of 44 patients. Rheumatol Int 14:253–255PubMedCrossRef Caramaschi P, Biasi D, Manzo T, Carletto A, Poli F, Bambara LM (1995) Anticentromere antibody-clinical associations: a study of 44 patients. Rheumatol Int 14:253–255PubMedCrossRef
16.
go back to reference McCarty GA, Rice JR, Bembe ML, Barada FA Jr (1983) Anticentromere antibody. Clinical correlations and association with favorable prognosis in patients with scleroderma variants. Arthritis Rheum 26:1–7PubMedCrossRef McCarty GA, Rice JR, Bembe ML, Barada FA Jr (1983) Anticentromere antibody. Clinical correlations and association with favorable prognosis in patients with scleroderma variants. Arthritis Rheum 26:1–7PubMedCrossRef
17.
go back to reference Miller HM, Littlejohn GO, Davidson A, Jones B, Topliss DJ (1987) The clinical significance of the anticentromere antibody. Br J Rheumatol 26:17–21PubMedCrossRef Miller HM, Littlejohn GO, Davidson A, Jones B, Topliss DJ (1987) The clinical significance of the anticentromere antibody. Br J Rheumatol 26:17–21PubMedCrossRef
18.
go back to reference Sun D, Martinez A, Sullivan KF, Sharp GC, Hoch SO (1996) Detection of anticentromere antibodies using recombinant human CENP-A protein. Arthritis Rheum 39:863–867PubMedCrossRef Sun D, Martinez A, Sullivan KF, Sharp GC, Hoch SO (1996) Detection of anticentromere antibodies using recombinant human CENP-A protein. Arthritis Rheum 39:863–867PubMedCrossRef
19.
go back to reference Martinez A, Sun D, Billings PB, Swiderek KM, Sullivan KF, Hoch SO (1998) Isolation and comparison of natural and recombinant human CENP-A autoantigen. J Autoimmun 11:611–619PubMedCrossRef Martinez A, Sun D, Billings PB, Swiderek KM, Sullivan KF, Hoch SO (1998) Isolation and comparison of natural and recombinant human CENP-A autoantigen. J Autoimmun 11:611–619PubMedCrossRef
Metadata
Title
Incidence and clinical correlation of anticentromere antibody in Thai patients
Authors
Krisaree Pakunpanya
Oravan Verasertniyom
Monchand Vanichapuntu
Prapaporn Pisitkun
Kitti Totemchokchyakarn
Kanokrat Nantiruj
Suchela Janwityanujit
Publication date
01-05-2006
Publisher
Springer-Verlag
Published in
Clinical Rheumatology / Issue 3/2006
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-005-0005-4

Other articles of this Issue 3/2006

Clinical Rheumatology 3/2006 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.